Gates Foundation's new world-first contraceptive for African women: what it means for Africa
The Bill & Melinda Gates Foundation is launching a new affordable long-term contraceptive in Africa, starting with Kenya.
The contraceptives, including a hormonal IUD effective for up to eight years and a contraceptive patch, aim to address obstacles such as cost and accessibility.
While receiving praise, concerns were raised about the ethical implications of externally funded family planning initiatives in Africa.
This innovation by the Bill and Melinda Gates foundation follows research showing poor health outcomes for African women, particularly those in underserved communities, and limited R&D funding for women's health conditions beyond cancer.
' Today, women's health issues are still too often misunderstood, misdiagnosed, or ignored. Although women generally live longer than men, they spend 25% more of their lives in poor health. ' Ru-fong Joanne Cheng, Director, Women's Health Innovations, Gates Foundation noted.
The new contraceptive: an affordable hormonal intrauterine device (IUD)—is designed to be effective for up to eight years, and will provide a discreet option for women in low-income households.
' A new hormonal IUD designed for affordability and a user-centered experience is being launched in Kenya, Nigeria, and possibly India, ' Dr Anita Zaidi, head of the Gender Equality Division at the Gates Foundation noted.
The device is inserted into the uterus, where it releases progestin, a synthetic hormone that thickens cervical mucus to prevent sperm from reaching and fertilising an egg.
Ru-fong described the revolutionary contraceptive patch, saying, 'I magine getting six months of contraceptive protection by pressing a small patch onto your skin. Discreet and self-administered.'
She further explained that the patch is embedded with microneedles containing progestin, which delivers protection over several months.
The foundation emphasized that the new programme will 'ensure that women and girls in low and middle-income countries can access the contraceptives and family planning information they want and thus exercise their right to decide whether to have children and, if so, when and how many.'
Dr. Anita also noted that the programme builds on the foundation's 25-year work in maternal and child health, aimed at ending preventable deaths, eliminating deadly infectious diseases, and lifting millions out of poverty by 2045.
'Many women in these communities want to have control over their reproductive health but do not use existing contraceptive methods because of male interference, concerns about side effects, or lack of access to options that meet their specific needs. As a result, nearly half of all pregnancies worldwide—about 45%—are unplanned ' the Foundation said
With the help of regional partners and government, the Gates foundation will expand access to the self-injectable contraceptive DMPA-SC to at least 35 countries, including Uganda, Senegal, Malawi, Nigeria, Zambia, and the Democratic Republic of Congo.
Other funded innovations include rapid testing for sexually transmitted infections, AI-enabled ultrasound devices, and vaginal health therapies.
Why Africa is the Focus
According to the Foundation, Sub-Saharan Africa has some of the highest rates of unmet need for family planning globally, with barriers ranging from cost and distance to health facilities to cultural opposition.
Many countries also face high rates of adolescent pregnancies, maternal mortality, and limited reproductive health infrastructure. By targeting Africa, the initiative seeks to provide longer-lasting, affordable options in regions where demand for family planning remains largely unmet.
As Melinda French Gates emphasized, ' Contraceptives are one of the most powerful tools we have. It puts the power in the hands of young girls and women to plan their families, and quite honestly, to plan their futures.'
Potential Implications
However, some critics raise concerns that contraceptive programs in Africa may be perceived as externally imposed population control.
This notion further suggests that the continent is being used as a testing ground for global health innovations, noting that similar large-scale rollouts are less visible in wealthier nations.
Considering concerns from billionaires like Elon Musk and western pro-life activists about declining populations in their own countries, which highlight contrasting demographic priorities, critics argue that the new program not only focuses on population control but also risks taking away one of Africa's major advantages: its growing population.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Abbott Laboratories shows growth in core products amid market shifts
In the first half (H1) of 2025, Abbott Laboratories performed well in the US medical device sector, with steady growth in its core product lines. According to leading data and analytics company GlobalData, some of Abbott's high-volume product lines declined in average selling price (ASP) in the first six months of 2025, when compared to reporting from the same period last year. However, Abbott's top revenue product lines maintained consistent ASPs across 2024 and 2025, which suggests that the company remains well-positioned and resistant to economic pressures, including those related to evolving tariff policies. When analysing Abbott's highest-volume products, some nuances emerge. Products that ranked highest by volume of sales in 2024 experienced modest increases in ASPs while those leading by volume in 2025 showed no change or a slight decline in ASPs. This pattern may reflect changing purchasing strategies among US healthcare facilities, potentially arising due to evolving priorities in public health and cost considerations. According to its recent financial report, Abbott delivered a strong first half in 2025, with its US medical device sales growing by 14.8% compared to H1 2024. GlobalData's latest data indicates continued strong performance across several key product lines, including MitraClip, Ensite X, and Tactiflex. In the US cardiovascular market, Abbott holds approximately 18% market share, according to GlobalData. Abbott's US diagnostics saw a modest decline in year-over-year sales in the second quarter of 2025, specifically in point-of-care and rapid diagnostics. This appears to be linked to reduced demand for Covid-19 testing, which had previously seen high demand. This shift in demand could be responsible for the changes in some of Abbott's high-volume sales. "Abbott Laboratories shows growth in core products amid market shifts" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
4 hours ago
- Yahoo
Boehringer's Hernexeos receives fast-tracked FDA approval
Boehringer Ingelheim has received fast-track approval from the US Food and Drug Administration (FDA) for its targeted therapy, Hernexeos (zongertinib tablets), to treat non-small cell lung cancer (NSCLC). This approval succeeds the positive results of the Phase Ib Beamion-LUNG 1 trial (NCT04886804), with the oral tyrosine kinase inhibitor (TKI) demonstrating an objective response rate (ORR) of 75% in patients with HER2-positive NSCLC who had received prior lines of platinum-based chemotherapy. Its FDA approval makes it the first oral treatment for HER2-positive NSCLC. Hernexeos also triggered a duration of response (DOR) of more than six months in 58% of the 71 patients previously treated with chemotherapy alone, while 27% of the 34 individuals with prior exposure to chemotherapy and a HER2 targeted therapy experienced a DOR of this length. Impacting 2%-4% of patients diagnosed with NSCLC, HER2 mutations are associated with poor prognosis and a higher risk of brain metastasis, while treatment options are highly limited in this population. Due to Hernexeos' potential to fulfil unmet needs in this indication, the FDA granted Boehringer priority review and breakthrough therapy designation last year. The therapy's full approval will likely rely on verification of clinical benefit in a confirmatory trial. Dr John Heymach, co-ordinating investigator on the Beamion-LUNG 1 trial and chair of thoracic/head and neck medical oncology at the MD Anderson Cancer Centre, said: 'The approval of zongertinib offers an effective and targeted treatment option for patients with HER2-mutant NSCLC in the US that not only elicits a durable response, but also has a manageable safety profile. 'In a patient population where there are currently limited treatment options, this approval represents a significant advancement in cancer care.' HER2-targeted therapy race heats up Though the current standard of care (SoC) for patients with HER2-mutated NSCLC still revolves around a platinum-based chemotherapy regimen, physicians are increasingly prescribing targeted therapies to improve outcomes. A notable example of this is AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan), which became the first HER2-targeting therapy to receive approval for NSCLC in 2022. Following its accelerated FDA approval, the drug has already reached blockbuster status – raking in $4.1bn in 2024 for the company, according to Pharmaceutical Technology's parent company, GlobalData. GlobalData predicts that the drug is on track to pull in $14.6bn by 2031, highlighting the lucrative nature of the targeted oncology market. However, Hernexeos has demonstrated a higher ORR of 75% compared with Enhertu's 56% in the DESTINY-Lung02 trial. The TKI has also proved efficacious in patients who had previously received treatment with an ADC, suggesting that the TKI could absorb some of Enhertu's market share. Looking ahead, the drug may also face competition from other targeted therapies currently in Phase III clinical trials, with GlobalData giving Bayer's TKI sevabertinib a likelihood of approval (LoA) score of 81% in this indication. "Boehringer's Hernexeos receives fast-tracked FDA approval" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Outrage as baby dies after genital mutilation in The Gambia
The death of a one-month-old baby girl who was the victim of female genital mutilation (FGM) in The Gambia has sparked widespread outrage. The baby was rushed to a hospital in the capital, Banjiul, after she developed severe bleeding, but was pronounced dead on arrival, police said. Although an autopsy is still being conducted to establish the cause of her death, many people have linked it to FGM, or female circumcision, a cultural practice outlawed in the West African state. "Culture is no excuse, tradition is no shield, this is violence, pure and simple," a leading non-governmental organisation, Women In Leadership and Liberation (WILL), said in a statement. Two women had been arrested for their alleged involvement in the baby's death, police said. The MP for the Kombo North District where the incident happened emphasised the need to protect children from harmful practices that rob them of their health, dignity, and life. "The loss of this innocent child must not be forgotten. Let it mark a turning-point and a moment for our nation to renew its unwavering commitment to protecting every child's right to life, safety, and dignity," Abdoulie Ceesay said. FGM is the deliberate cutting or removal of a female's external genitalia. The most frequently cited reasons for carrying it out are social acceptance, religious beliefs, misconceptions about hygiene, a means of preserving a girl or woman's virginity, making her "marriageable", and enhancing male sexual pleasure. The Gambia is among the 10 countries with the highest rates of FGM, with 73% of women and girls aged 15 to 49 having undergone the procedure, with many doing so before the age of six years. 'I wanted my clitoris back' - FGM survivor WILL founder Fatou Baldeh told the BBC that there was an increase in FGM procedures being performed on babies in The Gambia. "Parents feel that if they cut their girls when they're babies, they heal quicker, but also, because of the law, they feel that if they perform it at such a young age, it's much easier to disguise, so that people don't know," she said. FGM has been outlawed in The Gambia since 2015, with fines and jail terms of up to three years for perpetrators, and life sentences if a girl dies as a result. However, there have only been two prosecutions and one conviction, in 2023. A strong lobby group has emerged to demand the decriminalisation of FGM, but legislation aimed at repealing the ban was voted down in parliament last year. FGM is banned in more than 70 countries globally but continues to be practised particularly in Africa's Muslim-majority countries, such as The Gambia. You may also be interested in: What is FGM, where does it happen and why? FGM survivor refuses to let mutilation define her life 'Why I broke the law to be circumcised aged 26' Go to for more news from the African continent. Follow us on Twitter @BBCAfrica, on Facebook at BBC Africa or on Instagram at bbcafrica BBC Africa podcasts Focus on Africa This Is Africa